Unveiling the Role of GLP-1 in Breast Cancer Care: A Comprehensive Study
Obesity, a well-established risk factor for breast cancer, has led to the exploration of innovative treatments like glucagon-like peptide 1 (GLP-1) receptor agonists for weight management. At the 2025 San Antonio Breast Cancer Symposium, researchers presented groundbreaking findings on the real-world use of GLP-1 among breast cancer patients and its potential impact on clinical outcomes, social determinants of health, and circulating tumor DNA (ctDNA).
The study, one of the largest of its kind, analyzed electronic health records from an impressive 708,406 breast cancer patients diagnosed between January 2011 and February 2025. Through AI-assisted data extraction, researchers delved into documented GLP-1 use, clinical factors, sociodemographic characteristics, and correlations with ctDNA testing and positivity.
Who's Embracing GLP-1 Therapy?
Surprisingly, only 7.6% of patients had documented GLP-1 use, primarily for diabetes, weight loss, cardiovascular issues, or obstructive sleep apnoea. Interestingly, GLP-1 therapy was more prevalent among specific patient groups: those with a body mass index of 30 or higher, non-Latinx Black patients, telemedicine users, and individuals living in rural areas. Conversely, use was lower among older patients (over 75), those with advanced-stage disease (stage IV), patients with HR-/HER2- tumors, Latinx and Asian patients, individuals with limited English proficiency, and those receiving care at community medical centers.
GLP-1's Impact on Tumor Activity
The study revealed a fascinating connection: GLP-1 use was associated with higher rates of ctDNA testing (2.8% vs. 1.5%) and lower ctDNA positivity (25.8% vs. 31.6%). This suggests a potential link between GLP-1 therapy and reduced circulating tumor activity, sparking questions about its potential role in oncology care beyond weight management.
Implications and Future Directions
This study highlights the complex interplay between clinical factors, sociodemographic characteristics, and social determinants of health (SDOH) in GLP-1 use. It also underscores disparities in access to this potentially beneficial therapy. Researchers emphasize the need for further studies to determine GLP-1's direct impact on breast cancer outcomes and to ensure equitable access for diverse patient populations.
This comprehensive analysis offers valuable insights into GLP-1's potential benefits in breast cancer care, paving the way for future research and potentially transforming oncology treatment approaches.
